{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T16:31:41Z","timestamp":1748277101280,"version":"3.40.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T00:00:00Z","timestamp":1635638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T00:00:00Z","timestamp":1635638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["DARU J Pharm Sci"],"DOI":"10.1007\/s40199-021-00424-6","type":"journal-article","created":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T05:02:47Z","timestamp":1635656567000},"page":"389-396","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Metformin in the management of fibrocystic breast disease: a placebo-controlled randomized clinical trial"],"prefix":"10.1007","volume":"29","author":[{"given":"Sadaf","family":"Alipour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadith","family":"Rastad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azin","family":"Saberi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Firoozeh","family":"Faiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arezoo","family":"Maleki-Hajiagha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3692-2870","authenticated-orcid":false,"given":"Mahboubeh","family":"Abedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,31]]},"reference":[{"issue":"1","key":"424_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.11648\/j.ass.20140201.12","volume":"2","author":"M Hosseini","year":"2014","unstructured":"Hosseini M, Tizmaghz A, Otaghvar HA, Shams M. The prevalence of fibrocystic changes of breast tissue of patients who underwent reduction mammoplasty in Rasool-Akram, Firuzgar and Sadr Hospitals during 2007\u20132012. Adv Surg Sci. 2014;2(1):5\u20138. https:\/\/doi.org\/10.11648\/j.ass.20140201.12.","journal-title":"Adv Surg Sci"},{"issue":"11","key":"424_CR2","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/S0002-8223(00)00383-7","volume":"100","author":"NK Horner","year":"2000","unstructured":"Horner NK, Lampe JW. Potential mechanisms of diet therapy for fibrocystic breast conditions show inadequate evidence of effectiveness. J Am Diet Assoc. 2000;100(11):1368\u201380. https:\/\/doi.org\/10.1016\/S0002-8223(00)00383-7.","journal-title":"J Am Diet Assoc"},{"issue":"5","key":"424_CR3","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1634\/theoncologist.11-5-435","volume":"11","author":"M Guray","year":"2006","unstructured":"Guray M, Sahin AA. Benign breast diseases: classification, diagnosis, and management. Oncologist. 2006;11(5):435\u201349. https:\/\/doi.org\/10.1634\/theoncologist.11-5-435.","journal-title":"Oncologist"},{"issue":"2","key":"424_CR4","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00404-008-0889-8","volume":"280","author":"II Gumus","year":"2009","unstructured":"Gumus II, Koktener A, Dogan D, Turhan NO. Polycystic ovary syndrome and fibrocystic breast disease: is there any association? Arch Gynecol Obstet. 2009;280(2):249\u201353. https:\/\/doi.org\/10.1007\/s00404-008-0889-8.","journal-title":"Arch Gynecol Obstet"},{"issue":"5","key":"424_CR5","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S0749-3797(18)31247-9","volume":"3","author":"H Pastides","year":"1987","unstructured":"Pastides H, Najjar MA, Kelsey JL. Estrogen replacement therapy and fibrocystic breast disease. Am J Prev Med. 1987;3(5):282\u20136.","journal-title":"Am J Prev Med"},{"issue":"1","key":"424_CR6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/0002-9378(86)90421-7","volume":"154","author":"H Vorherr","year":"1986","unstructured":"Vorherr H. Fibrocystic breast disease: pathophysiology, pathomorphology, clinical picture, and management. Am J Obstet Gynecol. 1986;154(1):161\u201379. https:\/\/doi.org\/10.1016\/0002-9378(86)90421-7.","journal-title":"Am J Obstet Gynecol"},{"key":"424_CR7","doi-asserted-by":"publisher","unstructured":"Eskandari A, Alipour S. Hormone replacement therapy and breast diseases: a matter of concern for the gynecologist. Arch Breast Cancer. 2019:113\u20139. https:\/\/doi.org\/10.32768\/abc.201963113-119.","DOI":"10.32768\/abc.201963113-119"},{"key":"424_CR8","doi-asserted-by":"publisher","unstructured":"Alipour S, Eskandari A. Prescribing oral contraceptives in women with breast diseases: a matter of concern for the gynecologist. Arch Breast Cancer. 2019:55\u201366. https:\/\/doi.org\/10.32768\/abc.20196255-68.","DOI":"10.32768\/abc.20196255-68"},{"issue":"1","key":"424_CR9","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12902-021-00824-4","volume":"21","author":"S Alipour","year":"2021","unstructured":"Alipour S, Abedi M, Saberi A, Maleki-Hajiagha A, Faiz F, Shahsavari S, Eslami B. Metformin as a new option in the medical management of breast fibroadenoma; a randomized clinical trial. BMC Endocr Disord. 2021;21(1):169. https:\/\/doi.org\/10.1186\/s12902-021-00824-4.","journal-title":"BMC Endocr Disord"},{"issue":"2","key":"424_CR10","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3233\/BD-160256","volume":"37","author":"A Talaei","year":"2017","unstructured":"Talaei A, Moradi A, Rafiei F. The evaluation of the effect of metformin on breast fibrocystic disease. Breast Dis. 2017;37(2):49\u201353. https:\/\/doi.org\/10.3233\/BD-160256.","journal-title":"Breast Dis"},{"issue":"8","key":"424_CR11","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1007\/s12094-013-1144-8","volume":"16","author":"SM Hadad","year":"2014","unstructured":"Hadad SM, Hardie DG, Appleyard V, Thompson AM. Effects of metformin on breast cancer cell proliferation, the AMPK pathway and the cell cycle. Clin Transl Oncol. 2014;16(8):746\u201352. https:\/\/doi.org\/10.1007\/s12094-013-1144-8.","journal-title":"Clin Transl Oncol"},{"issue":"21","key":"424_CR12","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1200\/JCO.2011.39.3769","volume":"30","author":"B Bonanni","year":"2012","unstructured":"Bonanni B, Puntoni M, Cazzaniga M, Pruneri G, Serrano D, Guerrieri-Gonzaga A, et al. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol. 2012;30(21):2593\u2013600. https:\/\/doi.org\/10.1200\/JCO.2011.39.3769.","journal-title":"J Clin Oncol"},{"issue":"9","key":"424_CR13","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1002\/ijc.29965","volume":"138","author":"H Cai","year":"2016","unstructured":"Cai H, Zhang Y, Han TK, Everett RS, Thakker DR. Cation-selective transporters are critical to the AMPK-mediated antiproliferative effects of metformin in human breast cancer cells. Int J Cancer. 2016;138(9):2281\u201392. https:\/\/doi.org\/10.1002\/ijc.29965.","journal-title":"Int J Cancer"},{"issue":"6","key":"424_CR14","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.clbc.2013.08.012","volume":"13","author":"C Campagnoli","year":"2013","unstructured":"Campagnoli C, Berrino F, Venturelli E, Abb\u00e0 C, Biglia N, Brucato T, et al. Metformin decreases circulating androgen and estrogen levels in nondiabetic women with breast cancer. Clin Breast Cancer. 2013;13(6):433\u20138. https:\/\/doi.org\/10.1016\/j.clbc.2013.08.012.","journal-title":"Clin Breast Cancer"},{"issue":"23","key":"424_CR15","doi-asserted-by":"publisher","first-page":"10067","DOI":"10.7314\/apjcp.2014.15.23.10067","volume":"15","author":"AD Tabrizi","year":"2014","unstructured":"Tabrizi AD, Melli MS, Foroughi M, Ghojazadeh M, Bidadi S. Antiproliferative effect of metformin on the endometrium\u2013a clinical trial. Asian Pac J Cancer Prev. 2014;15(23):10067\u201370. https:\/\/doi.org\/10.7314\/apjcp.2014.15.23.10067.","journal-title":"Asian Pac J Cancer Prev"},{"key":"424_CR16","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.yrtph.2017.12.023","volume":"92","author":"T Adak","year":"2018","unstructured":"Adak T, Samadi A, \u00dcnal AZ, Sabuncuo\u011flu S. A reappraisal on metformin. Regul Toxicol Pharmacol. 2018;92:324\u201332. https:\/\/doi.org\/10.1016\/j.yrtph.2017.12.023.","journal-title":"Regul Toxicol Pharmacol"},{"issue":"2","key":"424_CR17","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/s0039-6109(05)70381-9","volume":"79","author":"J Katz","year":"1999","unstructured":"Katz J, Melzack R. Measuremnt of pain. Surg Clin North Am. 1999;79(2):231\u201352. https:\/\/doi.org\/10.1016\/s0039-6109(05)70381-9.","journal-title":"Surg Clin North Am"},{"issue":"11","key":"424_CR18","first-page":"580","volume":"74","author":"E Castillo","year":"2006","unstructured":"Castillo E, Garibay M, Mirabent F. Effect of alpha dihidroergocriptine in patients with fibrocystic breast disease. Ginecol Obstet Mex. 2006;74(11):580\u20134.","journal-title":"Ginecol Obstet Mex"},{"issue":"1","key":"424_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1658-3612(11)70151-2","volume":"6","author":"KR Murshid","year":"2011","unstructured":"Murshid KR. A review of mastalgia in patients with fibrocystic breast changes and the non-surgical treatment options. Journal of Taibah University Medical Sciences. 2011;6(1):1\u201318. https:\/\/doi.org\/10.1016\/S1658-3612(11)70151-2.","journal-title":"Journal of Taibah University Medical Sciences"},{"key":"424_CR20","doi-asserted-by":"publisher","unstructured":"Rajswaroob U, Kannan R, Kannan NS, Tirouaroul T effectiveness of Centchroman on regression of Fibroadenosis and Mastalgia. J Clin Diagn Res 2016;10(10):PC10-PC14. doi: https:\/\/doi.org\/10.7860\/JCDR\/2016\/20108.8604.","DOI":"10.7860\/JCDR\/2016\/20108.8604"},{"key":"424_CR21","doi-asserted-by":"publisher","unstructured":"Jahdi F, Tolouei R, Samani LN, Hashemian M, Haghani H, Mojab F, et al. Effect of evening primrose oil and Vitamin B6 on pain control of cyclic mastalgia associated with fibrocystic breast changes: a triple-blind randomized controlled trial. Shiraz E-Med J. Online ahead of Print ; 20(5):e81243. https:\/\/doi.org\/10.5812\/semj.81243.","DOI":"10.5812\/semj.81243"},{"issue":"8","key":"424_CR22","first-page":"466","volume":"20","author":"SM Mirhashemi","year":"2017","unstructured":"Mirhashemi SM, Sahmani M, Salehi B, Reza JZ, Taghizadeh M, Moussavi N, et al. Metabolic response to omega-3 fatty acids and vitamin e co-supplementation in patients with fibrocystic breast disease: a randomized, double-blind, placebo-controlled trial. Arch Iran Med. 2017;20(8):466\u201373.","journal-title":"Arch Iran Med"},{"issue":"9","key":"424_CR23","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1007\/s00125-017-4318-z","volume":"60","author":"CJ Bailey","year":"2017","unstructured":"Bailey CJ. Metformin: historical overview. Diabetologia. 2017;60(9):1566\u201376. https:\/\/doi.org\/10.1007\/s00125-017-4318-z.","journal-title":"Diabetologia."},{"issue":"6","key":"424_CR24","doi-asserted-by":"publisher","first-page":"909","DOI":"10.4161\/cc.8.6.7933","volume":"8","author":"IN Alimova","year":"2009","unstructured":"Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE, Thor AD. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle. 2009;8(6):909\u201315. https:\/\/doi.org\/10.4161\/cc.8.6.7933.","journal-title":"Cell Cycle"},{"issue":"4","key":"424_CR25","doi-asserted-by":"publisher","first-page":"214","DOI":"10.5152\/jtgga.2016.15200","volume":"17","author":"D Micallef","year":"2016","unstructured":"Micallef D, Micallef S, Schembri-Wismayer P, Calleja-Agius J. Novel applications of COX-2 inhibitors, metformin, and statins for the primary chemoprevention of breast cancer. Journal of the Turkish German Gynecological Association. 2016;17(4):214. https:\/\/doi.org\/10.5152\/jtgga.2016.15200.","journal-title":"Journal of the Turkish German Gynecological Association"},{"issue":"12","key":"424_CR26","doi-asserted-by":"publisher","first-page":"896","DOI":"10.18632\/oncotarget.387","volume":"2","author":"S Del Barco","year":"2011","unstructured":"Del Barco S, Vazquez-Martin A, Cuf\u00ed S, Oliveras-Ferraros C, Bosch-Barrera J, Joven J, et al. Metformin: multi-faceted protection against cancer. Oncotarget. 2011;2(12):896. https:\/\/doi.org\/10.18632\/oncotarget.387.","journal-title":"Oncotarget"},{"issue":"2","key":"424_CR27","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/jnci\/djaa082","volume":"113","author":"I Pimentel","year":"2021","unstructured":"Pimentel I, Chen BE, Lohmann AE, Ennis M, Ligibel J, Shepherd L, Hershman DL, Whelan T, Stambolic V, Mayer I, Hobday T. The effect of metformin vs placebo on sex hormones in Canadian cancer trials group MA. 32. JNCI: Journal of the National Cancer Institute. 2021;113(2):192\u20138. https:\/\/doi.org\/10.1093\/jnci\/djaa082.","journal-title":"JNCI: Journal of the National Cancer Institute"},{"issue":"3","key":"424_CR28","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.clbc.2012.03.004","volume":"12","author":"C Campagnoli","year":"2012","unstructured":"Campagnoli C, Pasanisi P, Abb\u00e0 C, Ambroggio S, Biglia N, Brucato T, et al. Effect of different doses of metformin on serum testosterone and insulin in non-diabetic women with breast cancer: a randomized study. Clin Breast Cancer. 2012;12(3):175\u201382. https:\/\/doi.org\/10.1016\/j.clbc.2012.03.004.","journal-title":"Clin Breast Cancer"},{"issue":"3","key":"424_CR29","doi-asserted-by":"publisher","first-page":"19","DOI":"10.17650\/1994-4098-2018-14-3-19-24","volume":"14","author":"EV Musina","year":"2018","unstructured":"Musina EV, Kogan IY. The effect of metformin on fibrocystic breast disease in women with insulin resistance. Tumors of Female Reproductive System. 2018;14(3):19\u201324.","journal-title":"Tumors of Female Reproductive System"},{"issue":"3","key":"424_CR30","doi-asserted-by":"publisher","first-page":"35","DOI":"10.17816\/JOWD68335-40","volume":"68","author":"EV Musina","year":"2019","unstructured":"Musina EV, Kogan IY. Application possibilities of biguanides for fibrocystic breast disease in women of reproductive age. J Obstet Women's Dis. 2019;68(3):35\u201340.","journal-title":"J Obstet Women's Dis"}],"container-title":["DARU Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-021-00424-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40199-021-00424-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-021-00424-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T09:58:27Z","timestamp":1744192707000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40199-021-00424-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,31]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["424"],"URL":"https:\/\/doi.org\/10.1007\/s40199-021-00424-6","relation":{},"ISSN":["2008-2231"],"issn-type":[{"type":"electronic","value":"2008-2231"}],"subject":[],"published":{"date-parts":[[2021,10,31]]},"assertion":[{"value":"10 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Institutional Research Board (Proposal Code: 97\u201301\u2013218-37,719) and the Ethics Committee (Approval ID: IR,TUMS.VCR.REC.1397.358) of Tehran University of Medical Sciences, Tehran, Iran.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all participants.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}